The DuraSite 2 was designed to develop topically delivered ocular drugs with enhanced tissue penetration. The patent will protect the technology’s delivery system and drugs formulated until 2029.
More Articles on Ophthalmology:
Femtosecond Laser Technology May Provide Alternative to Corneal Keratoplasty
Cataract Surgery Improve Vision in Retinitis Pigmentosa Sufferers, Study Says
Atlantic Eye Center in New Jersey Turns 25
